

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

HuH-28

RRID:CVCL_2955

Type: Cell Line

Proper Citation

RRID:CVCL_2955

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2955

Proper Citation: RRID:CVCL_2955

Description: Cell line HuH-28 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Intrahepatic cholangiocarcinoma

Defining Citation: [PMID:2852388](#), [PMID:2856443](#), [PMID:9290701](#), [PMID:20164919](#), [PMID:21451941](#), [PMID:22460905](#), [PMID:25877200](#), [PMID:26956050](#), [PMID:27231123](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31077409](#), [PMID:39026794](#)

Comments: Population: Japanese., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: Biliary tract cancer cell line atlas.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HuH-28

Synonyms: HUH-28, HuH28, HUH28

Cross References: CLO:CLO_0050855, ArrayExpress:E-MTAB-783, BioSample:SAMN03470952, BioSample:SAMN03472037, BioSample:SAMN10987843, cancercellines:CVCL_2955, Cell_Model_Passport:SIDM01735, ChEMBL-Cells:ChEMBL3308110, Cosmic:924163, Cosmic:1373551, Cosmic:2674045, DepMap:ACH-000808, FANTOM5_SSTAR:10536-107G5, GEO:GSM887147, GEO:GSM888219, IARC_TP53:28291, JCRB:JCRB0426, PharmacDB:HuH28_638_2019, Progenetix:CVCL_2955, RCB:RCB1943, TKG:TKG

0438, Wikidata:Q54896845

ID: CVCL_2955

Record Creation Time: 20220427T220622+0000

Record Last Update: 20260905T180818+0000

Ratings and Alerts

No rating or validation information has been found for HuH-28.

No alerts have been found for HuH-28.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Entrialgo-Cadierno R, et al. (2026) Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. Cancer cell, 44(6), 1218.

Liu CT, et al. (2026) Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. Cancer research communications, 6(3), 616.

Taguchi D, et al. (2025) Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866. International journal of molecular sciences, 26(3).

Bekric D, et al. (2024) The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells. PloS one, 19(4), e0302050.

Cai TT, et al. (2024) Septin 9 expression regulates 'don't eat me' signals and identifies an immune-epithelial class of intrahepatic cholangiocarcinoma. Molecular oncology, 18(10), 2369.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Jamnongsong S, et al. (2022) Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma. iScience, 25(10), 105182.

Gopinathan P, et al. (2020) Exploring Circulating Tumor Cells in Cholangiocarcinoma Using a Novel Glycosaminoglycan Probe on a Microfluidic Platform. *Advanced healthcare materials*, 9(10), e1901875.

Lendvai G, et al. (2020) The Effect of Methylselenocysteine and Sodium Selenite Treatment on microRNA Expression in Liver Cancer Cell Lines. *Pathology oncology research : POR*, 26(4), 2669.